Primary Central Nervous System Diffusing Large Cell LymphomaNCT07007611
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
An observational study of Primary Central Nervous System Diffusing Large Cell Lymphoma, run by jiahong Deng.
Trial summary
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma. The main questions it aims to answer are: Can surgery and gamma knife prolong the survival period of patients with primary central diffuse large B-cell… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Primary Central Nervous System Diffusing Large Cell Lymphoma
- How many people
- 76 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2006to 1 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: A retrospective analysis was conducted on data from patients diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) at Nanfang Hospital between December 2006 and December 2023. A total of 76 patients were included in this study, with follow-up continuing until July 2024.
Who may be able to join
- pathologically confirmed PCNS-DLBCL complete clinical records detailing treatment methods and surgical approaches.
Who cannot join
- incomplete systemic treatment data loss to follow-up after initial contact prior receipt of whole-brain radiotherapy.
About this study
Official title: The Role of Surgical Resection AND Stereotactic Radiosurgery in PCNS-DLBCL: A Retrospective Analysis of Clinical Benefits
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma. The main questions it aims to answer are:
Can surgery and gamma knife prolong the survival period of patients with primary central diffuse large B-cell lymphoma? Participants who have already incorporated surgery and gamma knife as part of the routine medical care for patients with primary central diffuse large B-cell lymphoma will answer questions about survival period within 5 years.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| primary central nervous system diffusing large cell lymphoma | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
The time from diagnosis to death of the patient
Measured: December 2006 and December 2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start1 Dec 2006
- Primary completion1 Dec 2023
- Study completion1 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Central Nervous System Diffusing Large Cell LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 76 participants (actual)
Sponsor and investigators
- Lead sponsor
- jiahong Deng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, jiahong Deng, Southern Medical University, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07007611
- Sponsor's protocol ID
- NFEC-2025-095
- Status last verified
- May 2025
- First submitted
- 28 May 2025
- Last updated
- 11 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Surgical Resection AND Stereotactic Radiosurgery in PCNS-DLBCL: A Retrospective Analysis of Clinical Benefits
- ClinicalTrials.gov ID
- NCT07007611
- Acronym / sponsor ID
- NFEC-2025-095
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 76 participants (actual)
- Lead sponsor
- jiahong DengUniversity, hospital or other
- Study start
- 1 Dec 2006 (actual)
- Primary completion
- 1 Dec 2023 (actual)
- Study completion
- 1 May 2025 (actual)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma. The main questions it aims to answer are:
Can surgery and gamma knife prolong the survival period of patients with primary central diffuse large B-cell lymphoma? Participants who have already incorporated surgery and gamma knife as part of the routine medical care for patients with primary central diffuse large B-cell lymphoma will answer questions about survival period within 5 years.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| primary central nervous system diffusing large cell lymphoma | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- A retrospective analysis was conducted on data from patients diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) at Nanfang Hospital between December 2006 and December 2023. A total of 76 patients were included in this study, with follow-up continuing until July 2024.
Key inclusion criteria (1 listed)
- pathologically confirmed PCNS-DLBCL complete clinical records detailing treatment methods and surgical approaches.
Key exclusion criteria (1 listed)
- incomplete systemic treatment data loss to follow-up after initial contact prior receipt of whole-brain radiotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival
Time frame: December 2006 and December 2023
The time from diagnosis to death of the patient
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Primary Central Nervous System Diffusing Large Cell Lymphoma, run by jiahong Deng.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: December 2006 and December 2023). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.